2111 | Humans |
1149 | Animals |
562 | Female |
560 | Male |
523 | Coronavirus Infections (epidemiology) |
475 | Molecular Sequence Data |
468 | Coronavirus Infections (virology) |
435 | Base Sequence |
347 | Adult |
308 | Middle Aged |
279 | Mice |
273 | Amino Acid Sequence |
267 | Coronavirus Infections (transmission) |
252 | Middle East Respiratory Syndrome Coronavirus (genetics) |
250 | Coronavirus Infections (prevention & control) |
248 | Middle East Respiratory Syndrome Coronavirus (isolation & purification) |
238 | Algorithms |
222 | Aged |
216 | Coronavirus Infections (diagnosis) |
205 | Disease Outbreaks |
195 | Middle East Respiratory Syndrome Coronavirus |
188 | Models, Molecular |
186 | Protein Binding |
171 | Middle East Respiratory Syndrome Coronavirus (immunology) |
167 | Cell Line |
165 | Phylogeny |
151 | Binding Sites |
148 | Saudi Arabia (epidemiology) |
147 | Adolescent |
141 | Middle East Respiratory Syndrome Coronavirus (physiology) |
139 | Young Adult |
134 | Software |
134 | DNA (chemistry) |
130 | Coronavirus Infections (immunology) |
124 | Nucleic Acid Conformation |
122 | Kinetics |
121 | Sequence Analysis, DNA (methods) |
116 | Republic of Korea (epidemiology) |
115 | Sequence Analysis, DNA |
113 | Coronavirus Infections (veterinary) |
113 | Child |
113 | Camelus (virology) |
111 | Protein Conformation |
108 | Coronavirus Infections (drug therapy) |
103 | Travel |
103 | Middle East Respiratory Syndrome Coronavirus (pathogenicity) |
98 | Disease Models, Animal |
98 | Antibodies, Viral (blood) |
97 | Aged, 80 and over |
95 | Coronavirus (isolation & purification) |
94 | Genome, Viral |
91 | Viral Vaccines (immunology) |
91 | Antiviral Agents (pharmacology) |
90 | Coronavirus (genetics) |
88 | Antibodies, Viral (immunology) |
86 | Thermodynamics |
86 | Spike Glycoprotein, Coronavirus (genetics) |
86 | Computational Biology (methods) |
85 | Time Factors |
85 | Peptides (chemistry) |
81 | Retrospective Studies |
81 | Coronavirus Infections (pathology) |
80 | Child, Preschool |
78 | Coronavirus Infections (therapy) |
77 | Saudi Arabia |
77 | Respiratory Tract Infections (virology) |
77 | Chlorocebus aethiops |
76 | Spike Glycoprotein, Coronavirus (immunology) |
76 | Computer Simulation |
76 | Chiroptera (virology) |
75 | Nucleic Acid Hybridization |
73 | Structure-Activity Relationship |
73 | Oligonucleotides (chemistry) |
72 | Mutation |
72 | Coronavirus |
72 | Camelus |
71 | Evolution, Molecular |
70 | Vero Cells |
70 | Spike Glycoprotein, Coronavirus (metabolism) |
70 | Sequence Alignment |
70 | Risk Factors |
70 | Escherichia coli (genetics) |
70 | Cells, Cultured |
70 | Antiviral Agents (therapeutic use) |
69 | Middle East Respiratory Syndrome Coronavirus (drug effects) |
69 | Mice, Inbred BALB C |
68 | Temperature |
68 | Antibodies, Neutralizing (immunology) |
66 | Sensitivity and Specificity |
66 | Respiratory Tract Infections (epidemiology) |
65 | Coronavirus Infections (mortality) |
63 | Global Health |
63 | Circular Dichroism |
62 | Zoonoses (virology) |
62 | Middle East (epidemiology) |
62 | Cross Infection (epidemiology) |
61 | Oligodeoxyribonucleotides (chemistry) |
61 | Dipeptidyl Peptidase 4 (metabolism) |
60 | Molecular Structure |
59 | RNA, Viral (genetics) |
59 | Cluster Analysis |
58 | Disease Reservoirs (virology) |
58 | Disease Outbreaks (prevention & control) |
57 | Virus Replication |
57 | Polymerase Chain Reaction |
57 | Models, Genetic |
57 | Genome |
56 | Real-Time Polymerase Chain Reaction |
56 | Enzyme-Linked Immunosorbent Assay |
56 | Electrophoresis, Polyacrylamide Gel |
56 | Crystallography, X-Ray |
55 | Severe Acute Respiratory Syndrome (virology) |
55 | Reproducibility of Results |
55 | Rats |
54 | Zoonoses (epidemiology) |
54 | Host-Pathogen Interactions |
54 | DNA (metabolism) |
53 | Virus Internalization |
53 | Middle East Respiratory Syndrome Coronavirus (classification) |
53 | Infant |
52 | Receptors, Virus (metabolism) |
52 | Models, Chemical |
51 | Treatment Outcome |
51 | Transcription Factors (metabolism) |
50 | Substrate Specificity |
50 | Hydrogen-Ion Concentration |
50 | Chromatography, High Pressure Liquid |
49 | Zoonoses (transmission) |
49 | RNA, Messenger (genetics) |
49 | Middle East |
49 | High-Throughput Nucleotide Sequencing |
49 | Genomics (methods) |
49 | DNA (genetics) |
48 | Severe Acute Respiratory Syndrome (epidemiology) |
48 | Sequence Homology, Amino Acid |
48 | Protein Structure, Tertiary |
48 | Cross-Sectional Studies |
48 | Antibodies, Neutralizing (blood) |
47 | Protein Structure, Secondary |
46 | Oligonucleotide Array Sequence Analysis (methods) |
46 | Molecular Weight |
46 | Infection Control (methods) |
46 | Coronavirus (physiology) |
45 | Reverse Transcriptase Polymerase Chain Reaction |
45 | DNA |
45 | Coronavirus (immunology) |
45 | Coronavirus (classification) |
45 | Communicable Diseases, Emerging (epidemiology) |
44 | Protein Multimerization |
44 | Peptides (immunology) |
44 | Lung (virology) |
43 | Viral Proteins (genetics) |
43 | Surveys and Questionnaires |
43 | SARS Virus (physiology) |
43 | SARS Virus (genetics) |
43 | Genetic Variation |
43 | Cattle |
42 | Prevalence |
42 | HEK293 Cells |
41 | Species Specificity |
41 | RNA (chemistry) |
41 | Dimerization |
41 | Computational Biology |
41 | Bacterial Proteins (metabolism) |
40 | Viral Proteins (metabolism) |
40 | Pneumonia, Viral (epidemiology) |
40 | Magnetic Resonance Imaging |
40 | Cross Infection (prevention & control) |
40 | Corpus Callosum (pathology) |
40 | Cloning, Molecular |
39 | Virus Replication (drug effects) |
39 | Viral Proteins (chemistry) |
39 | Transcription, Genetic |
39 | Spike Glycoprotein, Coronavirus (chemistry) |
39 | Pandemics |
39 | Models, Biological |
39 | Gene Expression |
39 | Epitopes (immunology) |
39 | DNA-Binding Proteins (metabolism) |
39 | Communicable Diseases, Emerging (virology) |
38 | Rabbits |
38 | Protein Folding |
38 | Promoter Regions, Genetic |
38 | Magnetic Resonance Spectroscopy |
38 | Dipeptidyl Peptidase 4 (genetics) |
38 | China |
37 | Syndrome |
37 | Mice, Inbred C57BL |
37 | Genome, Human |
37 | Databases, Genetic |
37 | DNA, Bacterial (genetics) |
37 | Cross Infection (transmission) |
37 | Cell Line, Tumor |
37 | Antibodies, Monoclonal (immunology) |
36 | T-Lymphocytes (immunology) |
36 | Models, Statistical |
36 | Coronavirus Infections (complications) |
35 | Seroepidemiologic Studies |
35 | Oligonucleotides, Antisense (pharmacology) |
35 | Oligodeoxyribonucleotides (chemical synthesis) |
35 | Ligands |
35 | Human |
35 | High-Throughput Nucleotide Sequencing (methods) |
35 | Base Composition |
34 | Population Surveillance |
34 | Neutralization Tests |
34 | Middle East respiratory syndrome |
34 | Middle East Respiratory Syndrome Coronavirus (metabolism) |
34 | DNA Replication |
34 | DNA Primers |
34 | Cricetinae |
34 | Coronavirus Infections (genetics) |
33 | World Health Organization |
33 | Recombinant Proteins (metabolism) |
33 | RNA, Messenger (metabolism) |
33 | Lung (pathology) |
32 | Viral Vaccines (genetics) |
32 | Oligonucleotides (genetics) |
32 | Infection |
32 | China (epidemiology) |
31 | Vaccination |
31 | Proteins (chemistry) |
31 | Peptides (metabolism) |
31 | Mutagenesis, Site-Directed |
31 | Health Personnel |
31 | Drug Design |
31 | Bacterial Proteins (genetics) |
30 | Viral Vaccines (administration & dosage) |
30 | Republic of Korea |
30 | Recombinant Proteins (chemistry) |
30 | Peptide Library |
30 | Nucleic Acid Denaturation |
30 | Molecular Conformation |
30 | In Vitro Techniques |
30 | Cross Infection (virology) |
30 | Blotting, Western |
29 | Zoonoses |
29 | Tumor Cells, Cultured |
29 | Transfection |
29 | Sequence Alignment (methods) |
29 | Public Health |
29 | Middle East Respiratory Syndrome Coronavirus (chemistry) |
29 | Coronavirus (pathogenicity) |
29 | Communicable Diseases, Emerging (prevention & control) |
29 | Antiviral Agents (chemistry) |
28 | Sequence Homology, Nucleic Acid |
28 | Pneumonia, Viral (virology) |
28 | Pneumonia, Viral (transmission) |
28 | Influenza, Human (epidemiology) |
28 | Escherichia coli (metabolism) |
28 | Dose-Response Relationship, Drug |
28 | Disease Outbreaks (statistics & numerical data) |
27 | SARS Virus (pathogenicity) |
27 | Health Knowledge, Attitudes, Practice |
27 | Coronavirus Infections (blood) |
27 | Catalysis |
27 | Binding, Competitive |
26 | Severity of Illness Index |
26 | Risk Assessment |
26 | Respiratory Tract Infections (transmission) |
26 | RNA, Viral (metabolism) |
26 | Polymerase Chain Reaction (methods) |
26 | HeLa Cells |
26 | Genomics |
26 | Genome, Bacterial |
26 | Gene Expression Regulation |
26 | Chiroptera |
25 | Stereoisomerism |
25 | SARS Virus (drug effects) |
25 | Recombination, Genetic |
25 | Prognosis |
25 | Plasmids |
25 | Oligonucleotides (chemical synthesis) |
25 | Oligodeoxyribonucleotides (metabolism) |
25 | Infant, Newborn |
25 | Incidence |
25 | Immunohistochemistry |
25 | Immunoglobulin G (blood) |
25 | Hot Temperature |
25 | Genotype |
25 | Coronavirus Infections (metabolism) |
25 | Coronavirus (drug effects) |
25 | Case-Control Studies |
25 | Alleles |
24 | Viral Load |
24 | United States |
24 | Solutions |
24 | SARS Virus (immunology) |
24 | Peptide Fragments (chemistry) |
24 | Oligonucleotide Array Sequence Analysis |
24 | Mice, Transgenic |
24 | Metagenomics (methods) |
24 | Macromolecular Substances |
24 | Infection Control |
24 | Immunoglobulin G (immunology) |
24 | Gene Expression Profiling |
24 | Epitope Mapping |
24 | Disease Transmission, Infectious |
24 | Conserved Sequence |
24 | Betacoronavirus |
23 | Virus Shedding |
23 | Viral Nonstructural Proteins (metabolism) |
23 | Viral Nonstructural Proteins (genetics) |
23 | Severe Acute Respiratory Syndrome (transmission) |
23 | Recombinant Proteins (genetics) |
23 | RNA, Viral (analysis) |
23 | Protein Domains |
23 | Models, Theoretical |
23 | Middle East Respiratory Syndrome Coronavirus (enzymology) |
23 | Islam |
23 | Immunization |
23 | Epitopes, T-Lymphocyte (immunology) |
23 | Disease Reservoirs |
23 | Contact Tracing |
23 | Betacoronavirus (genetics) |
23 | Bacterial Proteins (chemistry) |
22 | Spectrophotometry, Ultraviolet |
22 | Severe Acute Respiratory Syndrome (immunology) |
22 | Repetitive Sequences, Nucleic Acid |
22 | Receptors, Virus (genetics) |
22 | Protein Biosynthesis |
22 | Prospective Studies |
22 | Peptides (chemical synthesis) |
22 | Peptide Hydrolases (metabolism) |
22 | Macaca mulatta |
22 | Influenza, Human (virology) |
22 | Coronavirus Infections |
22 | Communicable Diseases, Emerging (transmission) |
22 | Cell Membrane (metabolism) |
22 | Antigens, Viral (immunology) |
21 | Water (chemistry) |
21 | Virus Internalization (drug effects) |
21 | Severe Acute Respiratory Syndrome (drug therapy) |
21 | Serine Endopeptidases (metabolism) |
21 | Respiratory Tract Infections (diagnosis) |
21 | Proteolysis |
21 | Pandemics (prevention & control) |
21 | Indicators and Reagents |
21 | Immunity, Innate |
21 | Gene Library |
21 | Epidemiological Monitoring |
21 | Epidemics |
21 | DNA-Binding Proteins (genetics) |
21 | Corpus Callosum (diagnostic imaging) |
20 | Virus Diseases (virology) |
20 | Survival Analysis |
20 | Static Electricity |
20 | Severe Acute Respiratory Syndrome (prevention & control) |
20 | Sequence Analysis, RNA |
20 | Sequence Analysis, RNA (methods) |
20 | SARS Virus |
20 | Oxidation-Reduction |
20 | Oligodeoxyribonucleotides |
20 | Mass Spectrometry |
20 | Hospitals |
20 | Genome, Viral (genetics) |
20 | Diagnosis, Differential |
20 | DNA, Single-Stranded (chemistry) |
20 | DNA Damage |
20 | DNA (analysis) |
20 | Cytokines (metabolism) |
20 | Bacteria (genetics) |
20 | Amino Acid Motifs |
19 | Viral Tropism |
19 | Vaccines, Synthetic (immunology) |
19 | Transcription Factors (genetics) |
19 | Tertiary Care Centers |
19 | Templates, Genetic |
19 | Spectrometry, Mass, Electrospray Ionization |
19 | Signal Transduction |
19 | Recombinant Proteins (immunology) |
19 | RNA (metabolism) |
19 | Protein Denaturation |
19 | Polymorphism, Single Nucleotide |
19 | Peptide Fragments (immunology) |
19 | Oligonucleotides (metabolism) |
19 | Oligonucleotide Probes |
19 | Internet |
19 | History, 21st Century |
19 | Genetic Vectors |
19 | Escherichia coli (enzymology) |
19 | Encephalitis (pathology) |
19 | Chromatography, Gel |
18 | Viruses (genetics) |
18 | Virus Diseases (epidemiology) |
18 | Surface Properties |
18 | Respiratory System (virology) |
18 | RNA, Viral (isolation & purification) |
18 | RNA (genetics) |
18 | Pneumonia, Viral (prevention & control) |
18 | Peptides (pharmacology) |
18 | Open Reading Frames |
18 | Nucleotide Motifs |
18 | Host Specificity |
18 | Epitopes |
18 | Epitopes (chemistry) |
18 | Databases, Protein |
18 | Comorbidity |
18 | Cell Division (drug effects) |
17 | Virus Attachment |
17 | Virulence |
17 | Viral Vaccines |
17 | United Arab Emirates (epidemiology) |
17 | Seasons |
17 | Risk |
17 | RNA |
17 | Protein Structure, Quaternary |
17 | Pregnancy |
17 | Pneumonia, Viral (diagnosis) |
17 | Peptide Fragments (metabolism) |
17 | Microscopy, Electron |
17 | Metagenomics |
17 | Metagenome |
17 | Light |
17 | Hydrogen Bonding |
17 | Genes, Viral |
17 | Drug Stability |
17 | Disease Reservoirs (veterinary) |
17 | DNA Repair |
17 | Consensus Sequence |
17 | Communicable Diseases, Emerging |
17 | Cohort Studies |
17 | CD4-Positive T-Lymphocytes (immunology) |
17 | Antiviral |
16 | Transcription Factors (chemistry) |
16 | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
16 | Sequence Analysis, Protein (methods) |
16 | SARS Virus (enzymology) |
16 | Ribavirin (therapeutic use) |
16 | Respiratory Tract Infections (prevention & control) |
16 | RNA-Binding Proteins (metabolism) |
16 | Promoter Regions, Genetic (genetics) |
16 | Probability |
16 | Polymers (chemistry) |
16 | Peptides |
16 | PCR |
16 | Osmolar Concentration |
16 | Oligopeptides (chemistry) |
16 | Mass Spectrometry (methods) |
16 | Immunity, Cellular |
16 | HIV-1 (immunology) |
16 | Cysteine Endopeptidases (chemistry) |
16 | Cell Survival (drug effects) |
16 | Binding Sites (genetics) |
16 | Bayes Theorem |
15 | Zoonoses (prevention & control) |
15 | Zoonoses (diagnosis) |
15 | United States (epidemiology) |
15 | Ultraviolet Rays |
15 | Support Vector Machine |
15 | Spectrometry, Fluorescence |
15 | Real-Time Polymerase Chain Reaction (methods) |
15 | Plasmids (genetics) |
15 | Phosphorylation |
15 | Oligosaccharides (chemistry) |
15 | Oligodeoxyribonucleotides (genetics) |
15 | Molecular Diagnostic Techniques (methods) |
15 | Lung (diagnostic imaging) |
15 | Influenza, Human (diagnosis) |
15 | Immune Evasion |
15 | Hydrolysis |
15 | Genes, Reporter |
15 | Escherichia coli Proteins |
15 | Encephalitis (etiology) |
15 | Encephalitis (diagnosis) |
15 | Drug Discovery |
15 | DNA Primers (genetics) |
15 | DNA Methylation |
15 | Cysteine Endopeptidases (metabolism) |
15 | Cross Reactions |
15 | Coronavirus Infections (psychology) |
15 | Coronaviridae (genetics) |
15 | Communicable Diseases, Emerging (diagnosis) |
15 | Communicable Disease Control |
15 | Chemical Phenomena |
15 | Catalytic Domain |
15 | CD8-Positive T-Lymphocytes (immunology) |
15 | Brain Diseases (pathology) |
15 | Base Pairing |
15 | Antibody Specificity |
14 | Viruses (isolation & purification) |
14 | Thionucleotides (pharmacology) |
14 | Severe Acute Respiratory Syndrome (pathology) |
14 | Sequence Analysis, Protein |
14 | Saccharomyces cerevisiae (genetics) |
14 | SARS Virus (isolation & purification) |
14 | Regulatory Sequences, Nucleic Acid |
14 | Receptors, Virus (chemistry) |
14 | Radiography |
14 | RNA, Small Interfering (genetics) |
14 | Pneumonia, Viral (drug therapy) |
14 | Peptide Nucleic Acids (chemistry) |
14 | Mutation (genetics) |
14 | Microscopy, Atomic Force |
14 | Inhibitory Concentration 50 |
14 | Health Personnel (statistics & numerical data) |
14 | Gene Expression Profiling (methods) |
14 | Fatal Outcome |
14 | Enzyme Inhibitors (pharmacology) |
14 | Electroencephalography |